References
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
- Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30(11):2214–2220.
- Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542–1551.
- Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174(1):88–101.
- Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A. 2004;59(3):255–263.
- Ureshino H, Kusaba K, Kidoguchi K, et al. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. Ann Hematol. 2019;98(2):465–471.
- Kamiya T, Ito C, Fujita Y, et al. The prognostic value of the controlling nutritional status score in patients with multiple myeloma. Leuk Lymphoma. 2020;61(8):1894–1900.
- Nagata A, Kanemasa Y, Sasaki Y, et al. Clinical impact of Controlling Nutritional Status (CONUT) score on the prognosis of patients with diffuse large B-cell lymphoma. Hematol Oncol. 2020;61(12):2995–2997.
- Sakurai A, Nakazato T. The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine. Leuk Lymphoma. 2020. DOI:10.1080/10428194.2020.1791847
- Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005;20:38–45.